GLP-1 receptor agonists × glycemic control

TrialLancet (London, England)2009

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

John B Buse et al.PubMed ↗Publisher ↗

What the trial testedrandomised · 464 people · 2009

Randomised comparison

Probably lowered glycemic control

−1.01mmol/L−1.37 to −0.65

As reported

difference −1.01 mmol/L, 95% CI −1.37 to −0.65

Randomised comparison

Probably lowered glycemic control

−45%−66% to −12%

Bigger than 4 in 10 for glycemic control

As reported

IRR 0.55, 95% CI 0.34–0.88

No range given

Reported lower adverse events & safety, no range given

−55%

Bigger than 8 in 10 for adverse events & safety

As reported

IRR 0.448, no interval

Three numbers in the abstract

the abstract, start to end

[0.20]; estimated treatment difference -1.01 mmol/L; 95% CI -1.37 to -0.65;

(estimated treatment rate ratio 0.448, p<0.0001) and minor hypoglycaemia less frequent with liraglutide than with exenatide (1.93 vs 2.60 events per patient per year; rate ratio 0.55; 95% CI 0.34 to 0.88; p=0.0131;

← favours treatmentfavours comparator →
could be chance
No interval given · direction only, strength unknown
Glycemic control
−1.01−1.37 to −0.65
Adverse events & safety
IRR 0.448
Glycemic control
IRR 0.550.34–0.88
GLP-1 receptor agonistsGlycemic controlAdverse events & safety
1 / 3

536 papers cite itlatest 60 shown

2009
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

2 trials

Full record →Abstract, authors, funding and every citing paper · PMID 19515413